ARTICLE | Clinical News
ATL1103: Completed Phase II enrollment
March 31, 2014 7:00 AM UTC
Antisense completed enrollment of 24 acromegalic patients in an open-label, European and Australian Phase II trial evaluating 3 doses of 200 mg ATL1103 in the first week of treatment, followed by once...